Our Products

Erlonat supplier

ERLONAT Erlotinib Drug Supplier

Anti Cancer Medicine
  • Generic Name: Erlotinib-
  • Trade Name: - ERLONAT 150mg - Manufactured By NATCO PHARMA LIMITED
  • Composition: ERLONAT:- Each film coated tablet contains Erlotinib Hydrochloride equivalent to Erlotinib 150, 100 and 25mg.
  • Description: - Erlotinib Hydrochloride (Erlotinib) is a human EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor. It is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is used as a first-line treatment (initial treatment for patients with NSCLC whose cancer has spread to other parts of the body), maintenance treatment (for advanced-stage NSCLC in patients whose cancer has not spread or grown after prior treatment with certain types of chemotherapy), and 2nd- or 3rd-line treatment for advanced-stage NSCLC in patients whose cancer has spread or grown after receiving at least one round of chemotherapy.
  • Mechanism of Action: - The drug follows Geftinat (Gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. By inhibiting the ATP, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.
  • Dosage and Administration:- Therapy should be initiated by a physician experiences in the treatment of patients with NSCLC. The recommended daily dose of Erlotinib is 150mg taken at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs. When dosage reduction is necessary, the Erlotinib dose should be reduced in 50mg decrements. It is highly advisable to administer the drug under strict medical supervision and advice.
  • Side Effects:- Everyone reacts differently to treatment with Erlotinib. Some people may have side effects, while others may not. It's important to know the most common side effects with Erlotinib. Some common side effects that may occur as a result of the usage of Erlonat tablets include - diarrhea, weakness, rash, cough, shortness of breath, loss of appetite, fatigue, nausea, dry skin, anorexia, abdominal pain, gastrointestinal bleeding, interstitial lung disease, eye disorder in some cases. It must not be used in mothers who are breastfeeding or are pregnant without proper medical attention. Please be sure to consult to your doctor before administering the drug.
  • Packaging:-
    • ERLONAT 25mg: Supplied in blister pack of 10's/bottle pack of 10 tablets
    • ERLONAT 100mg: Supplied in blister pack of 10's/bottle pack of 30 tablets
    • ERLONAT 150mg: Supplied in blister pack of 10's/bottle pack of 30 tablets
  • Storage: - Store between 15 and 30 Degree C
  • Our Commitment: - We are suppler of Erlonat and other anticancer drugs across the all over Aisa at very cheap and affordable prices. We assure you of the best of the quality and services.


Quick Enquiry

Quick Contact !


55, Office No: 303, 3rd Floor,
Darya Ganj, Delhi-110002, India.

Mr. Sumit Gupta
(M): - +91 - 9811278800
(Tel): - +91-11-23269395, 43511880
(E): -

(QQID):- 1665876238
(Skype ID): -aurelpharma

Visit also our social profiles:

Scroll to top